Abexinostat - Xynomic Pharmaceuticals

Drug Profile

Abexinostat - Xynomic Pharmaceuticals

Alternative Names: CG-781; CRA-024781; PCI-24781; S 78454

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group
  • Developer GlaxoSmithKline; Massachusetts General Hospital; Pharmacyclics; Servier; University of California at San Francisco
  • Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Phase I/II Sarcoma
  • No development reported Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 01 Jun 2018 Xynomic Pharmaceuticals plans a phase I/II trial for Breast cancer (Combination therapy) in 2018 or 2019
  • 01 Jun 2018 Xynomic Pharmaceuticals plans a pivotal clinical trial for Diffuse large B cell lymphoma (Second-line therapy or greater, Monotherapy) in China in 2018 or 2019
  • 01 Jun 2018 Xynomic Pharmaceuticals plans a pivotal clinical trial for Follicular lymphoma (Second-line therapy or greater, Monotherapy) in China in 2018 or 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top